Irvine, CA, February 26, 2026 – Johnson & Johnson recently announced the U.S. launch of CEREGLIDE™ 42 and CEREGLIDE™ 57 aspiration catheters, along with the INNERGLIDE™ 7 delivery aid, as the latest additions to its aspiration-first stroke portfolio. These devices complete the CEREGLIDE™ family and are designed to help physicians reach and remove distal* clots more consistently, while simplifying procedural decisions and supporting performance across a broad range of ischemic stroke cases.
“We designed this multi-axial system to address procedural challenges physicians face when treating stroke,” said Christian Cuzick, Worldwide President, Neurovascular, MedTech, Johnson & Johnson. “With this expanded portfolio, we’re simplifying decisions, enhancing consistency across device sizes, and reinforcing our commitment to helping improve patient outcomes.”
CEREGLIDE™ 42 and CEREGLIDE™ 57 are built with a proprietary, variable-stiffness1 construction that provides flexible1 distal* navigation and supportive proximal control. Both catheters are intended to integrate seamlessly into existing neurointerventional workflows, offering:
- Hydrophilic coating1 for reduced friction in tortuous anatomy
- Radiopaque (based on benchmark testing) tip marker for fluoroscopic visibility
- Easily track to the M2** with TruCourse™ Technology
“Accessing distal occlusions remains one of the biggest technical challenges we face, especially in smaller or more tortuous vessels,” said Ameer E. Hassan2, DO, FAHA, FSVIN, Neuroscience Institute, Valley Baptist Medical Center, Harlingen, Texas. “In my experience, CEREGLIDE 42 and 57 track reliably while maintaining strong proximal support, even over multiple passes.3 That balance of flexibility and control gives me greater confidence when performing aspiration-first thrombectomy in more complex anatomy.”
INNERGLIDE™ 7 is a delivery aid designed to support the advancement of large-bore catheters like CEREGLIDE™ 71 to distal* clot locations***. It features a hydrophilic-coated shaft, 1.5 cm soft distal tip, and compatibility with 0.024” guidewires, offering added control and support during complex device delivery.
“Reaching the M2 segment with large-bore aspiration systems can be technically demanding,” said Dr. Hassan. “INNERGLIDE 7 provides the additional support needed to consistently deliver CEREGLIDE 71 into more distal targets with smoother navigation and less resistance. I am a firm believer in delivery catheter technology like Innerglide.”
The CEREGLIDE™ family of catheters now includes 42, 57, and 71 aspiration catheters, providing a range of catheters designed for performance, consistency, and compatibility across procedures.
Cardiovascular Solutions from Johnson & Johnson MedTech
Across Johnson & Johnson, we are tackling the world’s most complex and pervasive health challenges. Through a cardiovascular portfolio that provides healthcare professionals with advanced mapping and navigation, miniaturized tech, and precise ablation we are addressing conditions with significant unmet needs such as heart failure, coronary artery disease, stroke, and atrial fibrillation. We are the global leaders in heart recovery, circulatory restoration and the treatment of heart rhythm disorders, as well as an emerging leader in neurovascular care, committed to taking on two of the leading causes of death worldwide in heart failure and stroke. For more information, visit here and connect on LinkedIn.
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more about our MedTech sector’s global scale and deep expertise in cardiovascular, orthopedics, surgery and vision solutions at thenext.jnjmedtech.com. Follow us at @JNJMedTech and on LinkedIn.
Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 related to the CEREGLIDE™ 42, CEREGLIDE™ 57, and INNERGLIDE™ 7. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: competition, including technological advances, new products and patents attained by competitors; uncertainty of commercial success for new products; the ability of the company to successfully execute strategic plans; impact of business combinations and divestitures; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; and global health care reforms and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.
© Johnson & Johnson and its affiliates 2026. All rights reserved.
US_NEU_ISCH_411224
Footnotes
*Distal refers to the M2
**Based on benchtop testing
***Based on preclinical testing and preclinical testing may not be indicative of clinical results
i With the CEREGLIDE family of catheters eliminating ID/OD compatibility concerns
1 501331844/Verification & Validation - CG42+CG57 Characterization Report. Version A.8. February 29, 2024.
2 Dr. Ameer E. Hassan serves as a consultant for Johnson & Johnson but was not compensated for this announcement
3 This intermediate catheter has not been evaluated for more than 3 clot retrieval attempts using direct aspiration
Media contact:
James Alley
Jalley1@its.jnj.com